Emcure Pharmaceuticals Ltd dividend

Emcure Pharmaceuticals Ltd dividend

stocks purchased

₹ 4.0 Cr

Volume transacted

stocks purchased

31.0 K

stocks traded

Last Updated time: 23 Jul 11:34 AM


Emcure Pharmaceuticals Ltd




Last updated : FY 2024

Key Highlights

    The Dividend per Share of Emcure Pharmaceuticals Ltd is ₹ 3 as of 2024 .a1#The Dividend Payout of Emcure Pharmaceuticals Ltd changed from 16.85 % on March 2019 to 22.6 % on March 2023 . This represents a CAGR of 6.05% over 5 years. a1#The Latest Trading Price of Emcure Pharmaceuticals Ltd is ₹ 1290 as of 23 Jul 11:27 .a1#The Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 0 crore on March 2019 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 6 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue


*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

Share Price Vs Dividend Yield


Historical Dividend Payout of Emcure Pharmaceuticals Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Emcure Pharmaceuticals Ltd

Mar '1917
Mar '200
Mar '214
Mar '2212
Mar '2323

* All values are a in %

Dividend per Share (DPS) Over Time



Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.

Dividend Yield Comparison With Top Peers





* All values are in %

Net Profit Vs Dividend Per Share


Emcure Pharmaceuticals Ltd




-34.35 (-2.59%)

stock direction

Last updated : 23 Jul 11:27

Overview of Dividend

Types of Dividend

Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.

Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.

Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.

Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


Historical Market Cap of Emcure Pharmaceuticals Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Emcure Pharmaceuticals Ltd

Mar '190
Mar '200
Mar '210
Mar '220
Mar '230
Mar '240

* All values are a in crore

About Emcure Pharmaceuticals Ltd

About Emcure Pharmaceuticals Ltd

    Emcure Pharmaceuticals Ltd. was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. The Company is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Emcure Pharmas were ranked as the largest pharmaceutical company in India in the gynecology, blood related and HIV antivirals therapeutic areas. It has 14 manufacturing facilities across India, which are capable in producing pharmaceutical and biopharmaceutical products of dosage forms, including oral solids, oral liquids, injectables including lipid, liposomal, lyophilized injectables, biologics, vaccines and complex APIs, including chiral molecules and cytotoxic products. The Company keeps a strong track record in developing portfolios of differentiated products across several platforms, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far. In year 1999, Lasor Drugs Limited was amalgamated with the Company. Thereafter, Emcure Laboratories Private Limited., Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiraral Mehta Sales Private Limited were amalgamated with Company during period 2001. The Company established facility in Kurkumbh in 2006 and then commenced operations of injectables facility in Hinjawadi. The facility established by Company's Subsidiary, Gennova Biopharmaceuticals Limited at Hinjawadi was made operational. The Company started operations in solid orals at facility in Jammu in 2009. During 2012, it acquired rights of BiCNUr, a branded oncology product prescribed for treatment of brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphoma. Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018. The Company has a portfolio of six commercialized and in-house manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase, commonly used for acute myocardial infraction, and the biosimilar for Pegylated-asparaginase, commonly used for treating patients with leukemia. It hold the global patent for use of Tenectaplase to treat Acute Ischemic Stroke as a second indication in 2021. The Company is proposing an Initial Public Offering of Rs 1100 Crore Equity Shares through Fresh Issue and an Offer for Sale upto 18,168,356 Equity Shares.

Emcure Pharmaceuticals Ltd News Hub


Shares of Emcure Pharmaceuticals debut on bourses

The equity shares of Emcure Pharmaceuticals (Scrip Code: 544210) are listed effective 10 J...

Read more

10 Jul 202409:15


Emcure Pharma makes strong debut on NSE; lists at 31% premium over issue price

The scrip was listed at Rs 240, a premium of 31.45% over the initial public offer (IPO) pr...

Read more

10 Jul 202410:45

up arrow

Unlimited trading at just

Rs. 399

Rs. 199